Format

Send to

Choose Destination
Vaccine. 2015 Dec 22;33(52):7506-12. doi: 10.1016/j.vaccine.2015.09.110. Epub 2015 Nov 1.

Designing malaria vaccines to circumvent antigen variability.

Author information

1
Institute for Global Health and Howard Hughes Medical Institute, University of Maryland School of Medicine, Baltimore, MD, USA; Malaria Research and Training Center, University of Sciences, Techniques and Technology, Bamako, Mali. Electronic address: aouattara@medicine.umaryland.edu.
2
Division of Population Health and Immunity, Walter and Eliza Hall Institute for Medical Research, Parkville, Australia; Department of Medical Biology, University of Melbourne, Melbourne, Australia. Electronic address: barry@wehi.edu.au.
3
Walter Reed Army Institute of Research, Silver Spring, MD, USA. Electronic address: sheetij.dutta.civ@mail.mil.
4
The Biomedical Primate Research Center, Rijswijk, Netherlands. Electronic address: remarque@bprc.nl.
5
Burnet Institute, Melbourne, Victoria, Australia; Department of Microbiology, Monash University, Victoria, Australia. Electronic address: beeson@burnet.edu.au.
6
Institute for Global Health and Howard Hughes Medical Institute, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: cplowe@medicine.umaryland.edu.

Abstract

Prospects for malaria eradication will be greatly enhanced by an effective vaccine, but parasite genetic diversity poses a major impediment to malaria vaccine efficacy. In recent pre-clinical and field trials, vaccines based on polymorphic Plasmodium falciparum antigens have shown efficacy only against homologous strains, raising the specter of allele-specific immunity such as that which plagues vaccines against influenza and HIV. The most advanced malaria vaccine, RTS,S, targets relatively conserved epitopes on the P. falciparum circumsporozoite protein. After more than 40 years of development and testing, RTS,S, has shown significant but modest efficacy against clinical malaria in phase 2 and 3 trials. Ongoing phase 2 studies of an irradiated sporozoite vaccine will ascertain whether the full protection against homologous experimental malaria challenge conferred by high doses of a whole organism vaccine can provide protection against diverse strains in the field. Here we review and evaluate approaches being taken to design broadly cross-protective malaria vaccines.

KEYWORDS:

Allele-specific efficacy; Cross-protection; Diversity; Heterologous; Malaria; Vaccine

PMID:
26475447
PMCID:
PMC4731100
DOI:
10.1016/j.vaccine.2015.09.110
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center